| Amy Welsh |
Amy Welsh is currently the Chief Commercial Officer at Agile Therapeutics, Inc. She previously worked as the Vice President-Marketing at Antares Pharma, Inc. from 2017 to 2020. Ms. Welsh completed her undergraduate degree at LaSalle University. |
| Scott M. Coiante |
Scott M. Coiante is currently the Chief Financial Officer, CAO & Senior VP at Agile Therapeutics, Inc. He previously worked as the Treasurer, Chief Accounting Officer & VP-Finance at Medarex, Inc. from 2002 to 2010. Prior to that, he was the Head-Financial Reporting at Ernst & Young LLP from 1989 to 2000. From 2010 to 2019, he held the position of CFO, Principal Accounting Officer & Senior VP at Agile Therapeutics, Inc. He also served as a Member of the New Jersey Technology Council. From 2019 to 2023, he was the Chief Financial Officer & Senior Vice President at Aprea Therapeutics AB and Aprea Therapeutics, Inc. He also held the position of Secretary at Aprea Therapeutics, Inc. Mr. Coiante completed his undergraduate degree at Villanova University. |
| Paul Korner |
Paul Korner is currently an Independent Director at Voltron Therapeutics, a Director at Versameb AG, the Chief Medical Officer at Agile Therapeutics, and a Principal at Laidlaw Private Equity LLC. He previously worked as an Executive Director-Medical Affairs at Berlex Laboratories, the VP-Medical Strategy & Clinical Development at Sarepta Therapeutics, the Vice President-Medical Affairs at Ferring Pharmaceuticals, the VP-Medical Affairs & Women's Healthcare at Bayer HealthCare Pharmaceuticals, the Chief Medical Officer & Executive Vice President at Ardelyx, and the Senior Vice President-Clinical Development at Sio Gene Therapies. He also served as the President of Ferring International Pharmascience Center US. Dr. Korner holds a doctorate from Loyola University New Orleans, an undergraduate degree from the University of Illinois, and an MBA from Coles College of Business. |
| Robert G. Conway |
Robert G. Conway is the founder. He founded R.G. Conway & Associates, Inc. in 1997, where he held the title of Principal. Currently, Mr. Conway is the Chief Supply Chain & Corporate Planning Officer at Agile Therapeutics, Inc. since 2004. He previously worked at Johnson & Johnson as a Principal. Mr. Conway obtained his undergraduate degree from New Jersey Institute of Technology. |
| Alfred F. Altomari |
Alfred F. Altomari is currently the Chairman & Chief Executive Officer at Agile Therapeutics, Inc. since 2016. He is also an Independent Director at Insmed, Inc. since 2012 and a Director at Trenton Area Soup Kitchen since 2015. Additionally, he serves as a Trustee at Drexel University. In his former positions, Mr. Altomari served as the Chief Executive Officer & Director at Barrier Therapeutics, Inc. from 2008 to 2011. He was also the Chairman at NB Therapeutics from 2010 to 2013 and Baudax Bio, Inc. from 2019 to 2022. Furthermore, he held director roles at DUSA Pharmaceuticals, Inc., Signum Biosciences, Inc., Auxilium Pharmaceuticals LLC, Societal CDMO, Inc., and Nitric Bio, Inc. He also served as a Trustee at BioNJ, Inc.Mr. Altomari obtained his undergraduate degree from Drexel University in 1982 and an MBA from Rider University in 1986. |
| Geoffrey P. Gilmore |
Geoffrey P. Gilmore's career history includes current and former positions as well as his education. Currently, he is the Chief Administrative Officer at Agile Therapeutics, Inc. Prior to this, he held various roles at different companies. From 1997 to 2008, he worked at Bristol Myers Squibb Co. as the Vice President & Senior Counsel-Law Department. Then, from 2008 to 2012, he served as the Secretary, Senior Vice President & General Counsel at Amicus Therapeutics, Inc. In 2002, he worked as a Senior Attorney at Wyeth Pharmaceuticals LLC. Additionally, he has experience as an Associate at Ballard Spahr LLP and Montgomery McCracken Walker & Rhoads LLP. In terms of education, he completed his undergraduate studies at Franklin & Marshall College and obtained a graduate degree from The University of Michigan Law School. |
| Sharon Barbari |
Sharon Barbari currently works at Agile Therapeutics, Inc., as Independent Director from 2020 and VYNE Therapeutics, Inc., as Independent Director from 2020. Ms. Barbari also formerly worked at Sonoma Pharmaceuticals, Inc., as Independent Director from 2014 to 2021, VYNE Pharmaceuticals Ltd., as Director, Menlo Therapeutics, Inc., as Director, The Association of Bioscience Financial Officers, as Director, Phytogen Life Sciences, as Director, Gilead Sciences, Inc., as Chief Financial Officer from 1998 to 2002, InterMune, Inc., as CFO, Senior VP-Finance & Administration from 2002 to 2004, Cytokinetics, Inc., as Chief Financial Officer, Secretary & Executive VP from 2012 to 2017, and Foote, Cone & Belding Healthcare, as Vice President-Strategic Planning. Ms. Barbari received her undergraduate degree from San Jose State University. |
| Josephine Torrente |
Josephine Torrente is an Independent Director at Agile Therapeutics, Inc. and a Director at Hyman, Phelps & McNamara PC. She previously worked as an Executive VP-Corporate & Regulatory Affairs at Sprout Pharmaceuticals, Inc. Ms. Torrente has an undergraduate degree from Case Western Reserve University, a graduate degree from The University of Alabama at Birmingham, and a graduate degree from Temple University Beasley School of Law. |
| Sandra A. Carson |
Sandra A. Carson is currently an Independent Director at Agile Therapeutics, Inc. She is also a Director of Reproductive Endocrinology & Infertility at both Yale University and Women & Infants Corp. Previously, she served as the Director of Reproductive Endocrinology & Professor at Brown University from 2007 to 2013. From 2013 to 2019, she was the Vice President of Education at the American College of Obstetricians & Gynecologists. Dr. Carson has also held positions as the President of the American Society for Reproductive Medicine, Head of Reproductive Endocrinology at the American Board of Obstetrics & Gynecology, Inc., and Council Member at the National Institute of Child Health & Human Development. She obtained her doctorate degree from Northwestern University. |
| Seth H. Z. Fischer |
Seth H. Z. Fischer is currently serving as an Independent Director at Marinus Pharmaceuticals, Inc., Lead Independent Director at Agile Therapeutics, Inc., Director at Esperion Therapeutics, Inc., and Independent Non-Executive Director at Milestone Pharmaceuticals, Inc. He is also an Advisor at Healthquest Capital Management Co LLC. In his former positions, Mr. Fischer served as the Chief Executive Officer & Director at VIVUS, Inc., Group Chairman at Biosense Webster, Inc., Group Chairman at Janssen Pharmaceuticals, Inc., Group Chairman at North American Pharmaceuticals Co., Chairman-Worldwide Franchise at Cordis Corp., and Group Chairman at Johnson & Johnson. He also held positions as Group Chairman at Scios, Inc., Chairman & President at Ortho-McNeil Pharmaceutical LLC, Director at BioSig Technologies, Inc., Director at Trius Therapeutics, Inc., and Director at Spectrum Pharmaceuticals, Inc.Mr. Fischer obtained his undergraduate degree from The Ohio University in 1977. |
| John W. Hubbard |
John W. Hubbard is currently the Vice Chairman at the Children's Brain Tumor Foundation. He is also the Chairman at Precision Medicine Group LLC, Signant Health, and Agile Therapeutics, Inc. Additionally, he holds positions as a Director at Life Sciences Pennsylvania, Science 37, Inc., Advarra, Inc., Genstar Capital Management LLC, and is a Member of the Drug Information Association and The American Society for Clinical Pharmacology & Therapeutics. In his former roles, Dr. Hubbard served as the President, Chief Executive Officer & Director at BioClinica, Inc. from 2015 to 2018. He was also the Chairman of the Association of Clinical Research Organizations from 2017 to 2018. Furthermore, he held positions as a Director at Transcelerate Biopharma, Inc., Lifesci Acquisition II Corp., and ICON plc. He was the Senior VP & Head-Development Operations at Pfizer Inc. from 2010 to 2015 and served as the Group President-Global Clinical Research Services at ICON plc and ICON Clinical Research, Inc.Dr. Hubbard completed his undergraduate studies at Santa Clara University and obtained a doctorate degree from the University of Tennessee. |
